1. Home
  2. REAL vs ACIU Comparison

REAL vs ACIU Comparison

Compare REAL & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The RealReal Inc.

REAL

The RealReal Inc.

HOLD

Current Price

$15.59

Market Cap

1.9B

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$3.55

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAL
ACIU
Founded
2011
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
213.3M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
REAL
ACIU
Price
$15.59
$3.55
Analyst Decision
Buy
Strong Buy
Analyst Count
8
2
Target Price
$16.57
$10.00
AVG Volume (30 Days)
2.6M
420.0K
Earning Date
02-19-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$662,789,000.00
$5,482,957.00
Revenue This Year
$17.10
N/A
Revenue Next Year
$10.90
$644.42
P/E Ratio
N/A
N/A
Revenue Growth
14.30
N/A
52 Week Low
$4.61
$1.43
52 Week High
$17.39
$4.00

Technical Indicators

Market Signals
Indicator
REAL
ACIU
Relative Strength Index (RSI) 48.66 53.90
Support Level $15.05 $3.24
Resistance Level $17.39 $3.90
Average True Range (ATR) 0.81 0.26
MACD -0.19 -0.01
Stochastic Oscillator 25.83 42.42

Price Performance

Historical Comparison
REAL
ACIU

About REAL The RealReal Inc.

The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: